Based on the key indicators related to Corvus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Corvus Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Corvus Pharmaceuticals' Property Plant And Equipment Net is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 18 M in 2024, whereas Other Liabilities is likely to drop slightly above 870.8 K in 2024. Key indicators impacting Corvus Pharmaceuticals' financial strength include:
Investors should never underestimate Corvus Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Corvus Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Corvus Pharmaceuticals.
Net Income
(28.38 Million)
Corvus
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Free Cash Flow
Change In Working Capital
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Begin Period Cash Flow
Other Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Property Plant Equipment
Property Plant And Equipment Net
Non Current Assets Total
Non Currrent Assets Other
Net Receivables
Capital Surpluse
Inventory
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Retained Earnings Total Equity
Net Invested Capital
Net Working Capital
Capital Lease Obligations
Long Term Investments
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Interest Income
Ebitda
Net Interest Income
Non Operating Income Net Other
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Corvus Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Corvus Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Corvus Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Corvus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corvus Pharmaceuticals. Check Corvus Pharmaceuticals' Beneish M Score to see the likelihood of Corvus Pharmaceuticals' management manipulating its earnings.
Corvus Pharmaceuticals Stock Summary
Corvus Pharmaceuticals competes with Mereo BioPharma, Terns Pharmaceuticals, PDS Biotechnology, Inozyme Pharma, and Hookipa Pharma. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Corvus Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Corvus Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Corvus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Corvus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Corvus Pharmaceuticals competition to find correlations between indicators driving Corvus Pharmaceuticals's intrinsic value. More Info.
Corvus Pharmaceuticals is rated fifth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Corvus Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Corvus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Corvus Pharmaceuticals Systematic Risk
Corvus Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Corvus Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Corvus Pharmaceuticals correlated with the market. If Beta is less than 0 Corvus Pharmaceuticals generally moves in the opposite direction as compared to the market. If Corvus Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Corvus Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Corvus Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Corvus Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Corvus Pharmaceuticals Thematic Clasifications
Corvus Pharmaceuticals is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in Corvus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Corvus Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Corvus Pharmaceuticals growth as a starting point in their analysis.
Corvus Pharmaceuticals November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Corvus Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Corvus Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Corvus Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Corvus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Corvus Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.